# The Safety and Effectiveness of ISIS 2922 in Patients With AIDS Who Have Cytomegalovirus (CMV) of the Eyes

> **NCT00002356** · PHASE2 · COMPLETED · sponsor: **Ionis Pharmaceuticals, Inc.**

## Conditions studied

- Cytomegalovirus Retinitis
- HIV Infections

## Interventions

- **DRUG:** Fomivirsen sodium

## Key facts

- **NCT ID:** NCT00002356
- **Lead sponsor:** Ionis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002356, "The Safety and Effectiveness of ISIS 2922 in Patients With AIDS Who Have Cytomegalovirus (CMV) of the Eyes". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00002356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*